Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05334108 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport
A Phase 1 study, sponsored by Emalex Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT05334108: Completed Phase 1 study, sponsored by Emalex Biosciences.
NCT05334108 is a Phase 1 study that has completed, run by Emalex Biosciences. The registered enrollment target is 56 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05334108, a Phase 1 study, has completed, sponsored by Emalex Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in healthy subjects.
Primary Outcome
Up to 46 blood samples will be collected at the indicated time points for pharmacokinetic analysis
Interventions
- DRUG Ecopipam
- COMBINATION_PRODUCT Cohort 1 Probe Substrate Cocktail
- DRUG Cohort 2 Probe Substrate
- COMBINATION_PRODUCT Cohort 3 Probe Substrate Cocktail
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2022-04-26 |
| Est. Completion | 2022-08-26 |
| Phase | Phase 1 |
What the finished NCT05334108 record still lists
NCT05334108 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which Ecopipam is the first listed.
NCT05334108 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05334108 about?
NCT05334108 is a clinical study titled "Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport". This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in healthy subjects.
What is the current status of trial NCT05334108?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2022-04-26. Estimated completion is 2022-08-26.
What interventions are being tested in trial NCT05334108?
The interventions under investigation include: Ecopipam (DRUG), Cohort 1 Probe Substrate Cocktail (COMBINATION_PRODUCT), Cohort 2 Probe Substrate (DRUG), Cohort 3 Probe Substrate Cocktail (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05334108?
This trial is sponsored by Emalex Biosciences, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05334108's enrollment target sits among peer trials
56 902nd of 2000 higher than 1,083 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI